高风险大麻使用:通过Delphi方法论为科学共识提供操作定义的建议
Clara Oliveras1,2,3, Pablo Rodrigo Guzman Cortez1,2, Laura Nuno1,2,3
1Addictions Unit, Psychiatry and Psychology Service, ICN, Hospital Clinic Barcelona, Barcelona, Spain.
European addiction research
|September 16, 2024
概括
高风险大麻使用被定义为每周消费超过4个标准联合单位 (SJU) 或大麻超过10%的THC强度. 这种定义有助于识别弱势群体,并为减少危害的战略提供信息.
科学领域:
- 公共卫生 公共卫生
- 成 药物 药物 药物 药物
- 大麻研究 大麻研究
背景情况:
- 大麻是全球广泛使用的精神活性物质.
- 大麻使用与身体,精神,社会和经济健康问题有关.
- 使用危险物质增加了有害后果的风险.
研究的目的:
- 为西班牙制定高风险大麻使用的操作定义.
- 为了在定义高风险大麻消费模式方面达成专家共识.
- 确定与大麻使用相关的特定脆弱性因素.
主要方法:
- 一项为期三轮的德尔菲研究,涉及西班牙45名专家.
- 在线调查使用利克特比例和开放式问题.
- 共识定义为≥75%的共识,使用标准联合单位 (SJU) 进行剂量.
主要成果:
- 高风险使用:每周>4个SJU (>28毫克THC) 或大麻>10%THC强度.
- 与其他药物并发使用和被确定为高风险的吸烟药物和服用途径.
- 易受伤害的群体包括21岁以下的个人,孕妇/哺乳期妇女,患有精神病或医疗问题的人以及某些专业人员.
结论:
- 操作定义阐明了西班牙的高风险大麻使用模式和脆弱性因素.
- 这个定义可以指导个人,专业人士和政策制定者预防和降低风险.
- 通过采用这一定义,可以促进基于证据的干预.
更多相关视频
07:31Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
7.0K
05:52Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
14.9K
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
01:12Hazard Ratio
96
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
96